相关临床试验
1117
288 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1907
终止
49
4.4%
招募中
156
14.0%
暂停
3
0.3%
撤回
52
4.7%
进行中（未招募）
225
20.1%
Unknown
61
5.5%
已完成
508
45.5%
Enrolling By Invitation
5
0.5%
尚未招募
58
5.2%
暂无批准数据
- Google has mapped all 9 billion possible single-letter genetic changes across the human genome with AlphaGenome Atlas and made the resource openly available to researchers worldwide. - The company reported that AI detected 25% of interval cancers previously missed in mammograms of 175,000 women in a study with Imperial College London and the UK's NHS. - Google's tuberculosis chest X-ray tool has screened over 25,000 X-rays across 40 locations in six nations, while its diabetic retinopathy model has supported more than 1.15 million screenings. - CEO Sundar Pichai framed the work around four focus areas: health, natural disaster and weather resilience, learning, and economic opportunity.
- Researchers used high-resolution atomic force microscopy and molecular dynamics simulations to directly visualize DNA-DNA recognition for the first time, confirming a mechanism proposed more than 20 years ago. - The study shows positively charged divalent ions such as magnesium and calcium act as molecular bridges that hold neighboring DNA helices in a groove-to-groove alignment. - The team identified specific DNA sequence motifs that form hotspots where pairing occurs more readily, regions that may matter when mutations disrupt normal cellular processes in cancer. - Findings, published in Nucleic Acids Research, may inform understanding of chromosome organization and support design of DNA origami for targeted drug delivery.
- A single dose of APL-10456, an adjuvanted recombinant protein subunit vaccine, induced broad cross-reactive T cell responses against all three rhinovirus species in healthy adults. - The Phase I randomized, double-blind, placebo-controlled study enrolled 144 participants, with the vaccine well tolerated and no serious adverse events reported. - APL-10456 targets a conserved protein antigen to overcome the roughly 180 genetically distinct rhinovirus strains that have historically frustrated vaccine development. - Apollo plans a Phase II trial in COPD patients in the first half of 2027, with Part B results in older adults expected in Q4 2026.
- Humanity Health Inc. and Quest Diagnostics have launched Humanity Biological Age, a scientifically validated biological age measurement, in the U.S. for the first time through questhealth.com. - The add-on costs $29 and requires no additional blood draw, integrating with select Quest health profile tests at approximately 2,000 patient service centers nationwide. - The model was developed with Imperial College London and trained on more than 306,000 UK Biobank participants followed for an average of 11.6 years, with validation on a separate cohort. - The report identifies which body systems influence biological age, including cardiovascular, metabolic, liver, kidney, blood, immune, hormonal, and bone and mineral health.
- Scientists at Stanford University and Arc Institute used AI genome language models Evo 1 and Evo 2 to design entirely new viruses capable of infecting E. coli bacteria. - The models, trained on trillions of nucleotides and roughly 15,000 viruses, generated 700,000 candidates; 16 proved viable, with some reproducing faster than the natural Phi X-174 virus. - The research, published in Science, could accelerate gene therapy and biotechnology breakthroughs but has drawn urgent warnings from biosecurity experts about potential misuse for biological weapons. - Biosecurity leaders Dr. Thomas Inglesby and Dr. Moritz Hanke called for strict laws prohibiting similar generative techniques on pathogens affecting humans, animals, or agricultural crops.
- Scientists at Imperial College London and The University of Manchester used genome mining to discover a new family of polyene antifungal agents published in Nature. - The lead compound Nys34 demonstrated reduced fungal burden in a mouse model of invasive aspergillosis without substantive signs of toxicity. - Nys34 employs a different mode of action than amphotericin, potentially overcoming resistance in emerging fungal pathogens. - The enzyme-based production platform offers a scalable, cost-effective alternative to complex chemical synthesis, potentially expanding access in lower-income regions.
- The U.S. FDA cleared C2N Diagnostics' PrecivityAD2 blood test for adults as young as 40 experiencing signs of cognitive impairment, making it the first FDA-cleared Alzheimer's blood test available to patients this young. - The clearance builds on nearly 20 years of Alzheimer's Drug Discovery Foundation (ADDF) investment in C2N's science, including a $7 million investment through its Diagnostics Accelerator. - PrecivityAD2 detects amyloid plaques in the brain with high diagnostic accuracy and is also being integrated into UK primary care pathways through the BEAD-PC study at Imperial College London. - The milestone reflects growing momentum of blood-based diagnostics in enabling earlier detection, sharper clinical trials, and a foundation for precision medicine and combination therapies.
- NHS data analysis by Imperial College London reveals a 69% increase in new type 2 diabetes diagnoses among women aged 20-29 between 2011 and 2024. - The rise is closely linked to increasing obesity rates, with body mass index at diagnosis climbing faster in younger adults than older age groups. - Early-onset type 2 diabetes is more aggressive, raising the risk of severe complications including heart attacks, strokes, and amputations over decades of elevated blood sugar. - The 2018 DiRECT trial demonstrated that 46% of newly diagnosed patients achieved remission within one year through a low-calorie diet, offering a pathway for reversal.
- A comprehensive analysis of roughly 215,000 NHS specialty training applications from 2021–2024 found overall success rates fell from 32.7% to 17.2%. - UK-trained ethnic minority doctors and applicants who are pregnant or on maternity leave experienced considerably lower chances of appointment, with disparities widening over time. - In 2024, Black doctors were up to 30 times less likely to be offered a training post than white applicants in some specialties, such as anaesthetics CT1. - Researchers and experts call for targeted support, mentoring, and objective bias assessment to build a fair and sustainable NHS workforce.
- A pilot trial of 21 women with long-standing anorexia nervosa found that three doses of psilocybin combined with talk therapy reduced eating disorder symptoms, with 48% achieving scores comparable to those without an eating disorder at three months. - Participants reported increased motivation to recover that persisted for up to one year after the trial ended, though no meaningful change in body mass index was observed. - The study lacked a control group, and researchers caution that further rigorous trials are needed before psilocybin therapy could become widely available for anorexia. - Anorexia nervosa carries the highest mortality rate of any psychiatric disorder, with affected individuals more than 18 times more likely to die by suicide than the general population.
